No Data
Seize the innovative leading value and explore the investment opportunities in Hong Kong stocks in the pharmaceutical sector after the deep pullback.
Since the beginning of this year, in the pharmaceuticals Sector, the Hong Kong stock market has demonstrated more cost-effective investment value compared to the A-shares.
Express News | Ascentage Pharma Group International Says Takeda Pharmaceuticals International AG Beneficially Owned 7.7% of Ordinary Shares Prior to Offering
Express News | Ascentage Pharma Group International Says J.P. Morgan, Citigroup Are Underwriters to US IPO
Express News | Ascentage Pharma Group International: Applied to List Adss on Nasdaq, Under Symbol “Aapg"
Express News | Ascentage Pharma Group International Files for U.S. IPO – SEC Filing
Kaiyuan Securities: Each subtype of hematological tumors has the potential to hatch "heavyweight bomb" drugs. Pay attention to Innovative Drugs companies.
The subtype of blood tumors is less aggressive with a longer treatment cycle, generally requiring long-term medication. Patients have relatively high viscosity and the potential for the emergence of "blockbuster" drugs.
No Data
